Robin Hayes
Experimental ALS Therapy Spurs Unprecedented Recoveries in Early Trials
In a remarkable departure from the typical expectations of neurodegenerative disease trials, an experimental therapy targeting a rare genetic form of amyotrophic lateral sclerosis (ALS) has yielded unprecedented functional recoveries in some patients. The therapeutic agent, ulefnersen—formerly known as jacifusen—was developed by Columbia University neurologist Dr. Neil Shneider in collaboration with Ionis Pharmaceuticals. Data published online in The Lancet reveal that two of the 12 patients treated for juvenile-onset FUS-mutant ALS experienced dramatic improvements, including the restoration of walking ability and respiratory independence, while another asymptomatic carrier has yet to develop disease signs after three years of continuous treatment.
· 5 min read

